{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:04:02Z","timestamp":1793930642448,"version":"4.8.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170213"],"award-info":[{"award-number":["82170213"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Key Research and Development Program of Chin"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1038\/s41375-025-02655-x","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T16:58:16Z","timestamp":1748451496000},"page":"1857-1864","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["High-dose cytarabine with idarubicin consolidation for acute myeloid leukemia in first complete remission: a randomized controlled trial"],"prefix":"10.1038","volume":"39","author":[{"given":"Yu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zinan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinquan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danian","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5732-0318","authenticated-orcid":false,"given":"Guopan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengcheng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoyang","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yirong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwen","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0178-691X","authenticated-orcid":false,"given":"Xuejie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9477-9286","authenticated-orcid":false,"given":"Dan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5064-2528","authenticated-orcid":false,"given":"Fen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiping","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiqing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9485-0249","authenticated-orcid":false,"given":"Hua","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4015-3952","authenticated-orcid":false,"given":"Qifa","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6176-7411","authenticated-orcid":false,"given":"Li","family":"Xuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"issue":"10393","key":"2655_CR1","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","volume":"401","author":"CD DiNardo","year":"2023","unstructured":"DiNardo CD, Erba HP, Freeman SD, Wei AH. Acute myeloid leukaemia. Lancet. 2023;401(10393):2073\u201386.","journal-title":"Lancet"},{"issue":"1","key":"2655_CR2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13045-023-01424-6","volume":"16","author":"RS Bhansali","year":"2023","unstructured":"Bhansali RS, Pratz KW, Lai C. Recent advances in targeted therapies in acute myeloid leukemia. J Hematol Oncol. 2023;16(1):29.","journal-title":"J Hematol Oncol"},{"key":"2655_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216767","volume":"588","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Chen W, Yu J, Pei S, Zhang Q, Shi J, et al. TP53 in MDS and AML: biological and clinical advances. Cancer Lett. 2024;588:216767.","journal-title":"Cancer Lett"},{"issue":"14","key":"2655_CR4","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJM199410063311402","volume":"331","author":"RJ Mayer","year":"1994","unstructured":"Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994;331(14):896\u2013903.","journal-title":"N Engl J Med"},{"issue":"27","key":"2655_CR5","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1200\/JCO.2012.47.4874","volume":"31","author":"AK Burnett","year":"2013","unstructured":"Burnett AK, Russell NH, Hills RK, Hunter AE, Kjeldsen L, Yin J, et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol. 2013;31(27):3360\u20138.","journal-title":"J Clin Oncol"},{"issue":"7","key":"2655_CR6","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1182\/blood-2017-04-777722","volume":"130","author":"KN Magina","year":"2017","unstructured":"Magina KN, Pregartner G, Zebisch A, W\u00f6lfler A, Neumeister P, Greinix HT, et al. Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis. Blood. 2017;130(7):946\u20138.","journal-title":"Blood"},{"key":"2655_CR7","unstructured":"Leukemia & Lymphoma Group, Chinese Society of Hematology, Chinese Medical Association. Chinese guidelines for the diagnosis and treatment of adult acute myeloid leukemia (not APL) (2021). Zhonghua Xue Ye Xue Za Zhi. 2021;42(8):617\u201323."},{"issue":"12","key":"2655_CR8","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345\u201377.","journal-title":"Blood"},{"issue":"5","key":"2655_CR9","doi-asserted-by":"publisher","first-page":"503","DOI":"10.6004\/jnccn.2023.0025","volume":"21","author":"DA Pollyea","year":"2023","unstructured":"Pollyea DA, Altman JK, Assi R, Bixby D, Fathi AT, Foran JM, et al. Acute myeloid leukemia, version 3.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2023;21(5):503\u201313.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"11","key":"2655_CR10","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1200\/JCO.2016.70.4551","volume":"35","author":"X Thomas","year":"2017","unstructured":"Thomas X, de Botton S, Chevret S, Caillot D, Raffoux E, Lemasle E, et al. Randomized phase II study of clofarabine-based consolidation for younger adults with acute myeloid leukemia in first remission. J Clin Oncol. 2017;35(11):1223\u201330.","journal-title":"J Clin Oncol"},{"issue":"13","key":"2655_CR11","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.1158\/1078-0432.CCR-19-3433","volume":"26","author":"H Wei","year":"2020","unstructured":"Wei H, Wang Y, Gale RP, Lin D, Zhou C, Liu B, et al. Randomized trial of intermediate-dose cytarabine in induction and consolidation therapy in adults with acute myeloid leukemia. Clin Cancer Res. 2020;26(13):3154\u201361.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2655_CR12","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1007\/s00277-015-2389-9","volume":"94","author":"DS Kim","year":"2015","unstructured":"Kim DS, Kang KW, Lee SR, Park Y, Sung HJ, Kim SJ, et al. Comparison of consolidation strategies in acute myeloid leukemia: high-dose cytarabine alone versus intermediate-dose cytarabine combined with anthracyclines. Ann Hematol. 2015;94(9):1485\u201392.","journal-title":"Ann Hematol"},{"issue":"9825","key":"2655_CR13","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","volume":"379","author":"S Castaigne","year":"2012","unstructured":"Castaigne S, Pautas C, Terr\u00e9 C, Raffoux E, Bordessoule D, Bastie JN, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379(9825):1508\u201316.","journal-title":"Lancet"},{"issue":"1","key":"2655_CR14","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13045-020-00975-2","volume":"13","author":"JE Cortes","year":"2020","unstructured":"Cortes JE, de Lima M, Dombret H, Estey EH, Giralt SA, Montesinos P, et al. Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia. J Hematol Oncol. 2020;13(1):137.","journal-title":"J Hematol Oncol"},{"issue":"9","key":"2655_CR15","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1200\/JCO.1989.7.9.1260","volume":"7","author":"SN Wolff","year":"1989","unstructured":"Wolff SN, Herzig RH, Fay JW, Phillips GL, Lazarus HM, Flexner JM, et al. High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: long-term follow-up and results. J Clin Oncol. 1989;7(9):1260\u20137.","journal-title":"J Clin Oncol"},{"issue":"17","key":"2655_CR16","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1200\/JCO.2012.46.4743","volume":"31","author":"M Schaich","year":"2013","unstructured":"Schaich M, Parmentier S, Kramer M, Illmer T, St\u00f6lzel F, R\u00f6llig C, et al. High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial. J Clin Oncol. 2013;31(17):2094\u2013102.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2655_CR17","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41409-021-01521-5","volume":"57","author":"E Shumilov","year":"2022","unstructured":"Shumilov E, Shakhanova I, Flach J, Schmidt N, Buerki S, Legros M, et al. Feasibility and efficacy of salvage allogeneic stem cell transplantation in AML patients relapsing after autologous stem cell transplantation. Bone Marrow Transpl. 2022;57(2):224\u201331.","journal-title":"Bone Marrow Transpl"},{"issue":"12","key":"2655_CR18","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/S1470-2045(18)30580-1","volume":"19","author":"U Platzbecker","year":"2018","unstructured":"Platzbecker U, Middeke JM, Sockel K, Herbst R, Wolf D, Baldus CD, et al. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. Lancet Oncol. 2018;19(12):1668\u201379.","journal-title":"Lancet Oncol"},{"issue":"12","key":"2655_CR19","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1182\/blood.2018886960","volume":"134","author":"A Venditti","year":"2019","unstructured":"Venditti A, Piciocchi A, Candoni A, Melillo L, Calafiore V, Cairoli R, et al. GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. Blood. 2019;134(12):935\u201345.","journal-title":"Blood"},{"issue":"4","key":"2655_CR20","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1200\/JCO.22.00715","volume":"41","author":"T Grob","year":"2023","unstructured":"Grob T, Sanders MA, Vonk CM, Kavelaars FG, Rijken M, Hanekamp DW, et al. Prognostic value of FLT3-internal tandem duplication residual disease in acute myeloid leukemia. J Clin Oncol. 2023;41(4):756\u201365.","journal-title":"J Clin Oncol"},{"issue":"7","key":"2655_CR21","doi-asserted-by":"publisher","first-page":"e2115991","DOI":"10.1001\/jamanetworkopen.2021.15991","volume":"4","author":"S Yu","year":"2021","unstructured":"Yu S, Fan Z, Ma L, Wang Y, Huang F, Zhang Q, et al. Association between measurable residual disease in patients with intermediate-risk acute myeloid leukemia and first remission, treatment, and outcomes. JAMA Netw Open. 2021;4(7):e2115991.","journal-title":"JAMA Netw Open"},{"issue":"12","key":"2655_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00591-4","volume":"11","author":"S Yu","year":"2021","unstructured":"Yu S, Lin T, Nie D, Zhang Y, Sun Z, Zhang Q, et al. Dynamic assessment of measurable residual disease in favorable-risk acute myeloid leukemia in first remission, treatment, and outcomes. Blood Cancer J. 2021;11(12):195.","journal-title":"Blood Cancer J"},{"issue":"1","key":"2655_CR23","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13045-021-01148-5","volume":"14","author":"MJL Aitken","year":"2021","unstructured":"Aitken MJL, Ravandi F, Patel KP, Short NJ. Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia. J Hematol Oncol. 2021;14(1):137.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2655_CR24","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13045-017-0502-3","volume":"10","author":"YJ Chang","year":"2017","unstructured":"Chang YJ, Wang Y, Liu YR, Xu LP, Zhang XH, Chen H, et al. Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis. J Hematol Oncol. 2017;10(1):134.","journal-title":"J Hematol Oncol"},{"issue":"29","key":"2655_CR25","doi-asserted-by":"publisher","first-page":"4632","DOI":"10.1200\/JCO.23.00101","volume":"41","author":"Y Ling","year":"2023","unstructured":"Ling Y, Xuan L, Xu N, Huang F, Fan Z, Guo Z, et al. Busulfan plus fludarabine compared with busulfan plus cyclophosphamide for AML undergoing HLA-haploidentical hematopoietic cell transplantation: a multicenter randomized phase III trial. J Clin Oncol. 2023;41(29):4632\u201342.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2655_CR26","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424\u201347.","journal-title":"Blood"},{"issue":"5","key":"2655_CR27","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1038\/s41375-019-0686-3","volume":"34","author":"S Yu","year":"2020","unstructured":"Yu S, Huang F, Wang Y, Xu Y, Yang T, Fan Z, et al. Haploidentical transplantation might have superior graft-versus-leukemia effect than HLA-matched sibling transplantation for high-risk acute myeloid leukemia in first complete remission: a prospective multicentre cohort study. Leukemia. 2020;34(5):1433\u201343.","journal-title":"Leukemia"},{"issue":"1","key":"2655_CR28","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13045-020-00859-5","volume":"13","author":"S Yu","year":"2020","unstructured":"Yu S, Huang F, Fan Z, Xuan L, Nie D, Xu Y, et al. Haploidentical versus HLA-matched sibling transplantation for refractory acute leukemia undergoing sequential intensified conditioning followed by DLI: an analysis from two prospective data. J Hematol Oncol. 2020;13(1):18.","journal-title":"J Hematol Oncol"},{"issue":"9","key":"2655_CR29","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/S1470-2045(20)30455-1","volume":"21","author":"L Xuan","year":"2020","unstructured":"Xuan L, Wang Y, Huang F, Fan Z, Xu Y, Sun J, et al. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. Lancet Oncol. 2020;21(9):1201\u201312.","journal-title":"Lancet Oncol"},{"issue":"1","key":"2655_CR30","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13045-020-01017-7","volume":"14","author":"L Xuan","year":"2021","unstructured":"Xuan L, Liu Q. Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. J Hematol Oncol. 2021;14(1):4.","journal-title":"J Hematol Oncol"},{"issue":"9","key":"2655_CR31","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1200\/JCO.2010.31.8121","volume":"29","author":"RB Walter","year":"2011","unstructured":"Walter RB, Gooley TA, Wood BL, Milano F, Fang M, Sorror ML, et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol. 2011;29(9):1190\u20137.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2655_CR32","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/bmt.2014.9","volume":"49","author":"C Anthias","year":"2014","unstructured":"Anthias C, Dignan FL, Morilla R, Morilla A, Ethell ME, Potter MN, et al. Pre-transplant MRD predicts outcome following reduced-intensity and myeloablative allogeneic hemopoietic SCT in AML. Bone Marrow Transpl. 2014;49(5):679\u201383.","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"2655_CR33","doi-asserted-by":"publisher","first-page":"357","DOI":"10.21873\/anticanres.13960","volume":"40","author":"JM Byun","year":"2020","unstructured":"Byun JM, Lee JO, Suh KJ, Lee J, Shin DY, Koh Y, et al. The role of anthracyclines in acute myeloid leukemia consolidation. Anticancer Res. 2020;40(1):357\u201366.","journal-title":"Anticancer Res"},{"issue":"1","key":"2655_CR34","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11596-018-1845-x","volume":"38","author":"JH Zhou","year":"2018","unstructured":"Zhou JH, Lin HQ, Shen Q, Hu LN, Li GQ, Sun XF, et al. Comparison of mitoxantrone in combination with intermediate-dose cytarabine versus high-dose cytarabine as consolidation therapies for young non-APL acute myeloid leukemia patients with favorable and intermediate cytogenetics. Curr Med Sci. 2018;38(1):51\u20137.","journal-title":"Curr Med Sci"},{"issue":"5","key":"2655_CR35","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1002\/hon.2806","volume":"38","author":"E Borlenghi","year":"2020","unstructured":"Borlenghi E, Cattaneo C, Cerqui E, Archetti S, Bertoli D, Bellotti D, et al. Postremission therapy with repeated courses of high-dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long-term outcome in European leukemia net favorable and intermediate-risk acute myeloid leukemia. Hematol Oncol. 2020;38(5):754\u201362.","journal-title":"Hematol Oncol"},{"issue":"19","key":"2655_CR36","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1200\/JCO.2010.33.7303","volume":"29","author":"M Schaich","year":"2011","unstructured":"Schaich M, R\u00f6llig C, Soucek S, Kramer M, Thiede C, Mohr B, et al. Cytarabine dose of 36 g\/m\u00b2 compared with 12 g\/m\u00b2 within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study. J Clin Oncol. 2011;29(19):2696\u2013702.","journal-title":"J Clin Oncol"},{"key":"2655_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217264","volume":"605","author":"Y Wang","year":"2024","unstructured":"Wang Y, Chang YJ, Chen J, Han M, Hu J, Hu J, et al. Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic haematopoietic stem cell transplantation in China: 2024 update. Cancer Lett. 2024;605:217264.","journal-title":"Cancer Lett"},{"issue":"16","key":"2655_CR38","doi-asserted-by":"publisher","first-page":"3840","DOI":"10.1182\/bloodadvances.2020002511","volume":"4","author":"PY Dumas","year":"2020","unstructured":"Dumas PY, Bertoli S, B\u00e9rard E, Leguay T, Tavitian S, Galtier J, et al. Delivering HDAC over 3 or 5 days as consolidation in AML impacts health care resource consumption but not outcome. Blood Adv. 2020;4(16):3840\u20133849.","journal-title":"Blood Adv"},{"issue":"10","key":"2655_CR39","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.1182\/blood-2004-03-1036","volume":"104","author":"W Kern","year":"2004","unstructured":"Kern W, Voskova D, Schoch C, Hiddemann W, Schnittger S, Haferlach T. Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood. 2004;104(10):3078\u201385.","journal-title":"Blood"},{"issue":"11","key":"2655_CR40","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1182\/bloodadvances.2018016378","volume":"2","author":"F Ravandi","year":"2018","unstructured":"Ravandi F, Walter RB, Freeman SD. Evaluating measurable residual disease in acute myeloid leukemia. Blood Adv. 2018;2(11):1356\u201366.","journal-title":"Blood Adv"},{"issue":"12","key":"2655_CR41","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","volume":"6","author":"NJ Short","year":"2020","unstructured":"Short NJ, Zhou S, Fu C, Berry DA, Walter RB, Freeman SD, et al. Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis. JAMA Oncol. 2020;6(12):1890\u20139.","journal-title":"JAMA Oncol"},{"issue":"31","key":"2655_CR42","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1200\/JCO.2012.45.9628","volume":"31","author":"M Terwijn","year":"2013","unstructured":"Terwijn M, van Putten WL, Kelder A, van der Velden VH, Brooimans RA, Pabst T, et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON\/SAKK AML 42A study. J Clin Oncol. 2013;31(31):3889\u201397.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2655_CR43","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/s41392-023-01614-1","volume":"8","author":"R Shao","year":"2023","unstructured":"Shao R, Zhang Y, He J, Huang F, Fan Z, Yang K, et al. Impact of genetic patterns on sorafenib efficacy in patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: a multi-center, cohort study. Signal Transduct Target Ther. 2023;8(1):348.","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"2655_CR44","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.ccell.2022.07.002","volume":"40","author":"D Bottomly","year":"2022","unstructured":"Bottomly D, Long N, Schultz AR, Kurtz SE, Tognon CE, Johnson K, et al. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. Cancer cell. 2022;40(8):850\u201364.e9.","journal-title":"Cancer cell"},{"issue":"6","key":"2655_CR45","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41556-020-0507-y","volume":"22","author":"JM Perry","year":"2020","unstructured":"Perry JM, Tao F, Roy A, Lin T, He XC, Chen S, et al. Overcoming Wnt-\u03b2-catenin dependent anticancer therapy resistance in leukaemia stem cells. Nat Cell Biol. 2020;22(6):689\u2013700.","journal-title":"Nat Cell Biol"},{"issue":"6","key":"2655_CR46","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s00277-012-1436-z","volume":"91","author":"M Hengeveld","year":"2012","unstructured":"Hengeveld M, Suciu S, Karrasch M, Specchia G, Marie JP, Muus P, et al. Intensive consolidation therapy compared with standard consolidation and maintenance therapy for adults with acute myeloid leukaemia aged between 46 and 60 years: final results of the randomized phase III study (AML 8B) of the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell\u2019Adulto (GIMEMA) Leukemia Cooperative Groups. Ann Hematol. 2012;91(6):825\u201335.","journal-title":"Ann Hematol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02655-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02655-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02655-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T18:22:28Z","timestamp":1757182948000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02655-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2655"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02655-x","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,28]]},"assertion":[{"value":"20 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}